Next week, 6,000 HIV researchers and experts are expected to make their way to Mexico City for the 10th International AIDS Society Conference on HIV Science, which will feature more than 1,000 abstracts highlighting the latest findings in HIV treatment, prevention, and public health policy.
Many trans women living with HIV may contract the virus because they or their sexual partners are intravenous drug users (IDU), finds a new study.
It turns out that you can trust gay men at high risk for HIV to take care of their health -- even if they have to remember to take an HIV prevention pill before sex.
Janssen Vaccines and Prevention B.V. is now rapidly advancing an experimental prime-boost HIV vaccine regimen, with plans announced to launch a large-scale "proof of concept" efficacy trial in women in late 2017/early 2018.
Brief IAS 2017 summaries of ongoing research on pre-exposure prophylaxis (PrEP), evaluating its long-term effectiveness and safety, patient experiences, and alternative dosing schedules, such as an on-demand regimen.
The vaccine candidate is called a "mosaic" vaccine because it includes snippets from a variety of different HIV subtypes, called clades. It is designed to work globally against most clades.
A vaginal ring that contains dapivirine was "liked" by 93% of adolescent participants in a small U.S. trial of the device that was presented at IAS 2017.
Dapivirine does not appear to be affected by a woman's vaginal microbiome composition when administered as a vaginal gel or film.
Cows injected with proteins mimicking HIV were able to rapidly produce broadly neutralizing antibodies in their blood as soon as 35 days after immunization, according to a new study.
Swaziland has dramatically reduced the number of new HIV infections while simultaneously getting a substantial portion of the HIV-positive population on treatment.